Narula N, Wong ECL, Marshall JK, et al. - This research sought to compare the efficacy of infliximab vs. vedolizumab for moderate to severe biologic-naïve ulcerative colitis (UC) using patient-level data from clinical trial program datasets. Researchers designed a post-hoc analysis of three UC clinical trial programs which included data on 795 biologic-naïve UC patients. They used multivariate logistic regression to adjust for potential confounders. The results showed that infliximab had higher rates of one-year corticosteroid-free clinical remission and endoscopic remission in the treatment of biologic-naïve UC, although infliximab and vedolizumab have similar efficacy in clinical symptom improvement.